Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement.

As a result, Pfizer will reduce its holding in Haleon to around 15% from around 22.6%. The settlement of both operations is expected to occur on Thursday, subject to certain conditions.

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022.

Pfizer also sold around £170 million worth of shares back to Haleon in an off-market share repurchase transaction. Haleon shares were down 0.2% as of 8:38 a.m. in London on March 19 after ...

Pfizer (NYSE: PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE: HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Pfizer Inc. has raised about £2.4 billion ($3.2 billion) from the sale of Haleon Plc shares, as it further reduces its stake in the UK consumer health company.

Pfizer (NYSE: PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE: HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...

Pfizer will receive all of the net proceeds, while Haleon won't receive any. Write to Najat Kantouar at [email protected] (END) Dow Jones Newswires January 14, 2025 12:16 ET (17:16 GMT) ...

Haleon HLN 0.14% posted a higher pretax profit for 2024 despite lower revenue, and said it expected further organic revenue and profit growth this year. The consumer-health giant, which was spun ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement.

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...